Bevacizumab for Radiation‐Induced (Radiculo)plexopathy
European Journal of Neurology · 2026-06 · 33 (6)
DOI: 10.1111/ene.70587 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 28.05.2026. Verfasst von Alberto Picca und 7 weiteren Autor:innen. Beteiligte Einrichtung: Service de Neuro-Oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Bevacizumab, Radiation Injuries, Angiogenesis Inhibitors. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Radiation‐induced (radiculo)plexopathy [RI(R)P] is a debilitating delayed neurological adverse event occurring in cancer survivors years after the irradiation of the brachial or lumbar plexuses. No effective treatments have been identified to date. The objective of this work was to evaluate the effectiveness of the anti‐VEGF bevacizumab in the treatment of RI(R)P.
Methods
We retrospectively identified patients diagnosed with contrast‐enhancing RI(R)P and treated with bevacizumab in the setting of an institutionally sponsored expanded access program over the last 10 years. Clinical, radiological, and neurophysiological records were reviewed.
Results
We identified nine patients manifesting with neurophysiological‐confirmed RI(R)P (brachial plexopathy, 4; lumbosacral radiculoplexopathy, 5) after a median of 13 years from radiotherapy for their cancer. Symptoms included focal weakness, paresthesia, cramps, hypoesthesia, amyotrophy, and pain. Patients received bevacizumab at 7.5 mg/kg/q2 weeks for a median of six cycles (range, three to nine cycles). Clinical improvement was noted in three cases and clinical stabilization in two. Patients treated within 2 years since symptom onset appeared as most likely to benefit. Enhancement reduction on follow‐up MRI was associated with the clinical benefit.
Discussion
Bevacizumab could be effective in the treatment of RI(R)P, particularly when patients are managed early in their disease. Further prospective clinical trials are warranted to validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Neuro-Oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France.
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
- OncoNeuroTox Group, Center for Patients With Neurological Complications of Oncologic Treatments Groupe Hospitalier Pitié-Salpêtrière et Hôpital Percy, Paris, France.
- Département de Neurophysiologie Clinique, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France.
- Service de Radiologie, Fondation Ophtalmologique de Rothschild, Paris, France.
- Service de Radiothérapie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France.
Zitieren
APA
Picca, A., Lenglet, T., Vandendries, C., Simon, J. M., Ducloie, M., Maisonobe, T., Ricard, D., & Psimaras, D. (2026). Bevacizumab for Radiation‐Induced (Radiculo)plexopathy. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70587
Vancouver
Picca A, Lenglet T, Vandendries C, Simon JM, Ducloie M, Maisonobe T, et al. Bevacizumab for Radiation‐Induced (Radiculo)plexopathy. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70587
BibTeX
@article{Picca2026,
author = {Picca, Alberto and Lenglet, Timothée and Vandendries, Christophe and Simon, Jean-Marc and Ducloie, Mathilde and Maisonobe, Thierry and Ricard, Damien and Psimaras, Dimitri},
title = {Bevacizumab for Radiation‐Induced (Radiculo)plexopathy},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {6},
doi = {10.1111/ene.70587}
}
EUVIMED